Direct Adenovirus-Mediated Insulin-Like Growth Factor I Gene Transfer Enhances Transplant Chondrocyte Function
- 20 January 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (2) , 117-129
- https://doi.org/10.1089/104303401750061186
Abstract
Cell-based cartilage-resurfacing procedures may be enhanced by the addition of insulin-like growth factor I (IGF-I) to the transplant biomatrix. Given the relatively short half-life of IGF-I in biological systems, however, maintenance of effective concentrations of this peptide necessitates either high initial doses, or repeated treatment. This study investigated IGF-I delivery via adenoviral gene therapy, targeting graftable articular chondrocytes. Cultured articular chondrocytes were infected with an E1-deleted adenoviral vector containing IGF-I-coding sequence under CMV promoter control. Increased adenovirus-IGF-I concentrations resulted in coordinate increase in IGF-I mRNA and ligand expression; however, chondrocyte matrix synthesis was maximized by the lower adenovirus-IGF-I concentration (100 MOI) without additional increase at 200 or 500 MOI. Using 100 MOI, infected monolayers produced medium IGF-I content of at least 10 ng/ml in each 48-hr period for 28 days, reaching a day 4 peak concentration of 66 ± 4.0 ng/ml. These concentrations were sufficient to produce significant stimulation of normal cartilage matrix gene expression. The concentration of secreted matrix products in medium from infected monolayers was increased up to 8-fold over uninfected control cultures. Moreover, compared with uninfected cultures, cells in infected cultures were more resistant to de-differentiation over time under serum-starved conditions, maintaining a normal chondrocyte molecular phenotype for at least 28 days. These data indicate that cultured chondrocytes are readily transduced by recombinant adenoviral vectors. The adenoviral-IGF transgene is abundantly expressed and its product secreted at therapeutic concentrations for at least 28 days, resulting in increased matrix biosynthesis and maintenance of the chondrocytic phenotype. Combined, this information suggests that there may be significant value in preimplantation adenoviral-IGF gene therapy for chondrocytes destined for cartilage resurfacing.Keywords
This publication has 43 references indexed in Scilit:
- Enhanced repair of extensive articular defects by insulin‐like growth factor‐I‐laden fibrin compositesJournal of Orthopaedic Research, 1999
- Coordinate upregulation of cartilage matrix synthesis in fibrin cultures supplemented with exogenous insulin‐like growth factor‐IJournal of Orthopaedic Research, 1999
- Differentiated cellular function in fetal chondrocytes cultured with insulin‐like growth factor‐I and transforming growth factor‐βJournal of Orthopaedic Research, 1998
- Regional gene therapy with a BMP‐2‐producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodentsJournal of Orthopaedic Research, 1998
- Repair of Articular Cartilage Defects Using Mesenchymal Stem CellsTissue Engineering, 1995
- Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation.Journal of Clinical Investigation, 1995
- Growth factor responsiveness of human articular chondrocytes: Distinct profiles in primary chondrocytes, subcultured chondrocytes, and fibroblastsJournal of Cellular Physiology, 1994
- Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfateOsteoarthritis and Cartilage, 1993
- In Vivo Osteochondrogenic Potential of Cultured Cells Derived From the PeriosteumClinical Orthopaedics and Related Research, 1990
- Factors involved in the regulation of proteoglycan metabolism in articular cartilageArthritis & Rheumatism, 1989